CALIXAR, the French biotech company specialized in the native isolation of membrane therapeutic targets and antigens, is proud to announce the official launch of the Protein and Membrane Technology Consortium (Prometeus). This project has received funding from the European Union’s H2020-MSCA-RISE-2018.
Coordinated by Prof. Beatrice VALLONE from the University of Rome, the aim of the Prometeus Consortium is to provide high-quality multidisciplinary knowledge through training and research on membrane protein and protein complexes as molecular tools for drug development and theranostics. The focus of the action is the creation of a synergistic pipeline to yield target membrane protein structure-function characterization and bioactive molecule design, harnessing the complementary skills from Academic and SME participants.
The role of CALIXAR within this consortium will be to bring its unique approach and recognized expertise in native membrane proteins solubilization and stabilization to enable drug discovery.
